Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Completed · Phase 1

Conditions studied: Ovarian Cancer, Peritoneal Cavity Cancer

In brief

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of cellular adoptive immunotherapy in treating patients with stage III or stage IV ovarian cancer or primary peritoneal cancer.

Key facts

Study ID

NCT00101257

Run by

Fred Hutchinson Cancer Center

People needed

18

Starts

2004-10-01

Expected to finish

2010-03-01

Last updated by the study team

2010-05-07

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.